Revenue nuggetsA few interesting bumps.
Rev $ 746k vs Prev Qtr of $ 535k or a 39% increase ! Annualized $ 3M?
Rev $ 746k vs prev year same Qtr of $ 547k or a 18% increase !
Royalty revenue ..."due to an increase in usage of the Company's IP from one customer" was $ 212k.
Baxter (exclusive Dist. Rights) Revenue was $ 167k for the Qtr (sadly & conservatively, Baxter's first of 3 tranches or $ 6.6MCAD$ - is being recognized (spread out) over 9 years and 11 months.
Yet despite this, revenues are increasing in the other categories i.e.: product revenues, and Royalty revenues.
Product Revenue was up 16% over the previous year - mainly due to EAA Sales increases. Are other countries (Japan, Italy, etc.) starting to use more diagnostics in order to provide more timely, and precise (as in precision medicine) absorption interventions? Is this a tacit recognition (even before the FDA rules on PMX) that guided diagnostics yeilds better outcomes? Pretty sure Ronco would agree with that last statement. I'm guessing the Japanese are coming around to this conclusion as well.
MM